Notation to File

RAPIDVAX

Heat Biologics, Inc.

Notation to File

NOTE TO THE FILE


SERIAL NUMBER:            90387503

DATE:                                03/12/2021

NAME:                               mwilson2

NOTE:         

Searched:                                                             
 X   Google                            
     Lexis/Nexis                       
 X   OneLook
     Wikipedia
     Acronym Finder                         Protest evidence reviewed
     Other:

Checked:                                                             
     Geographic significance          
     Surname                          
     Translation
     ID with ID/CLASS mailbox

     Checked list of approved Canadian attorneys and agents

Discussed file with
Attorney/Applicant via:
        phone                               Left message with
    X   email                               Attorney/Applicant

     Requested Law Library search       X   Issued Examiner’s Amendment
     for:                                   and entered changes in TRADEUPS

        PRINT        DO NOT PRINT           Added design code in TRADEUPS
     Description of the mark
     Translation statement                  Re-imaged standard character
                                            drawing
     Negative translation statement             
     Consent of living individual           Contacted TM MADRID ID/CLASS
                                            about misclassified definite ID
 X   Changed TRADEUPS to:
amend Class 5 ID

     OTHER:

From: Byrne, Peter G. <peter.byrne@morganlewis.com>
Sent: Thursday, March 11, 2021 10:06 PM
To: Wilson, Marynelle <Marynelle.Wilson@USPTO.GOV>; Washington Trademark e-Filings <trademarks@morganlewis.com>
Cc: Dubow, Rachelle A. <rachelle.dubow@morganlewis.com>; Kagan, Jennifer A. <jennifer.kagan@morganlewis.com>; Byrne, Peter G. <peter.byrne@morganlewis.com>
Subject: RE: U.S. Trademark Application for RAPIDVAX (Docket No. 114358-0002/Serial No. 90387503)

 

Hello Ms. Wilson,

 

The proposed amendment is acceptable to our client. Please proceed with the Examiner’s Amendment.

 

Thank you,

 

Peter

 

Peter G. Byrne

Morgan, Lewis & Bockius LLP

One Market, Spear Street Tower | San Francisco, CA 94105

Direct: +1.415.442.1335 | Main: +1.415.442.1000 | Fax: +1.415.442.1001

peter.byrne@morganlewis.com | www.morganlewis.com

Assistant: Yelena Lolua | +1.415.442.1474 | yelena.lolua@morganlewis.com

 

 

From: Wilson, Marynelle <Marynelle.Wilson@USPTO.GOV>
Sent: Thursday, March 11, 2021 10:28 AM
To: Washington Trademark e-Filings <trademarks@morganlewis.com>
Cc: Dubow, Rachelle A. <rachelle.dubow@morganlewis.com>; Byrne, Peter G. <peter.byrne@morganlewis.com>; Kagan, Jennifer A. <jennifer.kagan@morganlewis.com>
Subject: U.S. Trademark Application for RAPIDVAX (Docket No. 114358-0002/Serial No. 90387503)
Importance: High

 

[EXTERNAL EMAIL]

Good afternoon Ms. Dubow,

 

I am the trademark examining attorney handling the trademark application for RAPIDVAX (Docket No. 114358-0002/Serial No. 90387503). I need to make a small amendment to the application in order to move it forward. I need to amend the Class 5 identification to read as follows:

 

International Class 5: Pharmaceutical preparations for the treatment or prevention of cancer, immune-related diseases, and infectious diseases

 

If this amendment is acceptable, I’ll issue an Examiner’s Amendment and conduct my final review before approving the mark for publication. Please let me know by Monday, March 15. If you have any questions, please feel free to call or email me.

 

Thanks and best regards,

Marynelle


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed